MedicalResearch.com Interview with:
Prof. Gary M. Halliday
Discipline of Dermatology, Bosch Institute
Central Clinical School
University of Sydney
Sydney, NSW, Australia
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The recently published article is a review paper- we reviewed previous laboratory studies of the effects of nicotinamide on normal pigment cells and on melanoma, and also the previous studies showing that nicotinamide can reduce rates of non-melanoma skin cancer (basal cell and squamous cell carcinoma) in high risk patients. We have not done any clinical investigations of nicotinamide as a preventive agent for melanoma.
MedicalResearch.com: What should clinicians and patients take away from your report?
Response: There is as yet no evidence of the safety or effectiveness of nicotinamide for melanoma prevention.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: The review paper suggests that clinical studies should now be done to investigate this.
MedicalResearch.com: Is there anything else you would like to add?
Response: Nicotinamide replenishes cells’ energy stores, which are depleted by UV exposure. This extra energy enables cells to repair any DNA damage more efficiently, and also helps to reduce the immune suppressive effects of sunlight on the skin.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Minocha R, Damian DL, Halliday GM. Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide?. Photodermatol Photoimmunol Photomed. 2017;00:1–8. https://doi.org/10.1111/phpp.12328
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.